Buscar
Mostrando ítems 1-3 de 3
Systemic CD4 immunity and PD-L1/PD-1 blockade immunotherapy
(MDPI, 2022)
Artículo / Artikulua,
PD-L1/PD-1 blockade immunotherapy has changed the therapeutic approaches for the treatment of many cancers. Nevertheless, the mechanisms underlying its efficacy or treatment failure are still unclear. Proficient systemic ...
Clinical landscape of LAG-3-targeted therapy
(Elsevier, 2022)
Artículo / Artikulua,
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions. LAG-3 is considered a next-generation ...
Understanding LAG-3 Signaling
(MDPI, 2021)
info:eu-repo/semantics/article,
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ...